Bethanechol was first synthesized in 1935, and it is a direct-acting parasympathomimetic agent that acts on postganglionic parasympathetic receptors.

Bethanechol may be utilized in spinal shock subjects who have recovered to the point of voluntary control of the urethra and in patients with a sensory and motor paralytic bladder.

**FDA Approved Uses**

- Postoperative urinary retention

- Postpartum nonobstructive urinary retention

- Neurogenic atony of the bladder